The gene encoding the neuronal nicotinic acetylcholine receptor ␣7 subunit (CHRNA7) is located on chromosome 15q13.2. This region was suggested to be involved in the etiopathogenesis of: (a) schizophrenia combined with a neurophysiological deficit; (b) lithiumresponsive bipolar disorder; and (c) familial catatonic schizophrenia (periodic catatonia). Therefore, members of a large family with periodic catatonia strongly supporting the chromosome 15q13-22 region were genotyped with polymorphic markers localized around the CHRNA7 locus. A recombination event distally of marker D15S144 leading to the exclusion of the CHRNA7 locus from this candidate region was detected in one branch of the pedigree. This result provides strong evidence that a gene located telomeric to CHRNA7 is causative for the pathogenesis of catatonic schizophrenia in this family.
The gene encoding the neuronal nicotinic acetylcholine receptor ␣7 subunit gene (CHRNA7), located on chromosome 15q13.2 according to the map provided by the International Human Genome Sequencing Consortium, 1 has been discussed as a candidate for schizophrenia and bipolar disorder. High levels of CHRNA7 gene expression were found in nuclei that receive sensory information, like the thalamic nuclei, the pontine nuclei, and the superior olive complex. 2 Reports on heavy smoking behavior among schizophrenics further supported the hypothesis that CHRNA7 might be involved in the etiopathogenesis of schizophrenia. 3 Freedman and associates reported a maximum lod score (Z = 5.3, = 0.0, P Ͻ 0.001) for polymorphic marker D15S1360 mapping in close vicinity to the CHRNA7 locus for a decrease in the normal inhibition of the response to the second of two identical auditory stimuli, detected by measuring an evoked potential occurring 50 ms after the stimulus (P50) in schizophrenics. 4 In a recent report, this finding was supported by the same group employing a transmission disequilibrium approach in 62 parent-child trios. 5 Furthermore, they found distinct promoter variants of CHRNA7 being highly associated with schizophrenia ( 2 = 12.06, P = 0.0005) by investigating more than 500 schizophrenic and control subjects. 6 Turecki and coworkers 7, 8 demonstrated that bipolar disorder (manic-depressive illness) combined with positive response to lithium treatment maps also to this region (lod score 3.46, P = 0.000014, for marker ACTC). Riley et al 9 found suggestive evidence for linkage of the locus with schizophrenia in Southern African Bantu families; Neves-Pereira et al 10 and Curtis et al 11 failed to detect linkage of CHRNA7 with schizophrenia. Lai and colleagues 12 found no association of an allelic 2-bp deletion variant of CHRNA7 with schizophrenia in a population-based association study.
Periodic catatonia 13 (SCZD10, MIM 605419), a familial subtype of catatonic schizophrenia, is a genetically heterogenous disorder characterized by psychomotoric disturbances with akinetic and hyperkinetic episodes, frequently accompanied by hallucinations and delusions. Successive episodes may lead to an increasingly severe residual catatonic state. Our group has recently reported confirmed linkage based on a dominant model of inheritance (maximum GENEHUNTER-PLUS lod score 3.57, P = 0.000026, at coordinate 35.3 cM) of polymorphic markers between D15S165 and D15S153 with periodic catatonia (Stö ber et al, 14 and unpublished data) by investigating 12 extended pedigrees. Of these, a large family ( Figure 2 ) was found to support strongly the chromosome 15 locus (maximum multipoint lod score 2.89, = 0.029, at D15S1042 (VITESSE)). The aim of present study was to narrow down this region by genotyping additional markers around the CHRNA7 locus to determine whether the gene should be considered as a candidate for mutational analysis.
According to Freedman et al 5 
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D15S153 by a genome-wide linkage scan (Stö ber et al, 14 and unpublished data). In order to decide whether CHRNA7 should be considered as a candidate for mutational analysis, we have genotyped the members of this family, many of whom were affected with catatonic schizophrenia, with additional markers. Of these were informative D15S1010, D15S144, D15S1040, ACTC, D15S968, D15S659, D15S1028, and D15S987, respectively. Genotyping led to the exclusion of CHRNA7 together with the duplication of exons 5-10 of this gene 15 from the region of interest due to a recombination event between D15S144 and D15S1040 in one branch of the pedigree (Figure 2) , narrowing further down the region to approximately 20.3 cM between markers D15S144 and D15S1028. A recombination between markers D15S659 (43.47 cM; not shown) and D15S1028 (45.62 cM; Figure 2 ) in proband 0935 defines the distal limit of the disease region.
Several positive linkage findings for psychiatric disorders have been reported for the chromosome 15q13-22 region. 4, 5, 7, 8, 14 Of these, manic-depressive illness and periodic catatonia share bipolarity as a common feature, thus providing evidence that pleiotrophic effects of different mutations within one gene may be responsible for different clinical phenotypes. However, a potential clustering of more than one disease gene in this region cannot be ruled out. In order to find the gene(s) responsible for the diseases, narrowing down the chromosomal region and exclusion of candidate genes should be of high priority.
The neuronal nicotinic acetylcholine receptor ␣7 subunit gene (CHRNA7) has been suggested as a candidate gene for schizophrenia, 4, 5 although, mutational analysis of the CHRNA7 coding region revealed no variant uniquely found in a significant proportion of schizophrenic patients so far. 16 Exclusion of CHRNA7 as a candidate for periodic catatonia in a large family by haplotype mapping with densely spaced markers strongly supports the notion that a gene located telomeric to CHRNA7 within a 20.3-cM region is causative for the disease in this family.
Methods

Clinical
The multiplex family was ascertained as previously described in detail.
14 Consistent diagnostic classification within the family segregating periodic catatonia described here was achieved by extensive clinical evaluation, and additional information was collected from different sources, including case history, medical records and/or family informants. The study was approved by the Ethics Committee of the University of Wuerzburg and all individuals participated after giving written consent.
Genotyping
Polymorphic markers around CHRNA7 were selected from the Marshfield map. Fragments were amplified in a T-GRADIENT Thermocycler (Biometra, Gö ttingen, Germany) in the presence of ␣-32 P-dCTP and separated
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Figure 2
Segregating of polymorphic markers around CHRNA7 with periodic catatonia. Affected family members are symbolized by black diamonds. Six polymorphic markers out of 24 totally tested within this region are shown. A recombination event distally from D15S144 in proband 0730 and descendants of 0730 led to exclusion of CHRNA7 from the chromosomal disease region (boxed). Haplotypes from deceased persons or persons not available for genotyping were deduced from the data of the previously reported linkage scan, 14 and given in brackets. The double-crossover at marker ACTC in proband 0825 (haplotypes 1, 3) is confirmed by the results of the linkage scan (Stö ber et al 14 and data not shown).
on 6% polyacrylamide gels. PCR was performed in a final volume of 25 l containing 60 ng of genomic DNA, 10 pmol of each primer, 200 M of each dNTP, 1.0 or 1.5 mM MgCl 2 , 50 mM KCl, 10 mM Tris-HCl (pH 8.3 at 25°C), 0.025 mg ml −1 BSA, 0.025% Tween 20, and 0.5 U of Taq DNA polymerase (Eurogentec, Seraing, Belgium). Gels were dried and exposed to Kodak X-OMAT AR films. Resulting alleles were integrated into the haplotype data set derived from the genome wide linkage scan described previously (Stö ber et al, 14 and unpublished data).
